DDInter141 DDInter1376
Avanafil is a phosphodiesterase-5 (PDE5) inhibitor used in the treatment of erectile dysfunction. In comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both [sildenafil] and [vardenafil] but less selectivity than [tadalafil], suggesting a relatively lower risk of visual disturbances associated with off-target PDE6 inhibition. It first received FDA approval on April 27, 2012, with subsequent EMA approval in June 2013.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Avanafil {u} (Compound) binds {v} (Gene) PDE5A
Avanafil {u} (Compound) is included by {v} (Pharmacologic Class) Phosphodiesterase 5 Inhibitors
Avanafil {u} (Compound) causes {v} (Side Effect) Tachycardia
Avanafil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aminoglutethimide
Avanafil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapagliflozin
Avanafil {u} may lead to a major life threatening interaction when taken with {v} Fedratinib
Avanafil {u} may lead to a major life threatening interaction when taken with {v} Fluconazole
Avanafil (Compound) binds PDE5A (Gene)
Avanafil (Compound) is included by Phosphodiesterase 5 Inhibitors (Pharmacologic Class)
Avanafil (Compound) causes Tachycardia (Side Effect)
Avanafil may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide
Avanafil may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Avanafil may lead to a major life threatening interaction when taken with Fedratinib
Avanafil may lead to a major life threatening interaction when taken with Fluconazole